Endotrophin is a risk marker of complications in CANagliflozin cardiovascular Assessment Study (CANVAS): a randomized controlled trial

• Rasmussen D.G.K.
• Hansen M.K.
• Blair J.
• Jatkoe T.A.
• Neal B.
• Karsdal M.A.
• Genovese F.

Abstract

Background. Enhanced de novo collagen type VI (COL VI) formation has been associated with kidney and cardiovascular fibrosis. We hypothesized that endotrophin (ETP), a product specifically generated during collagen type VI formation, may be prognostic for heart failure (HF), cardiovascular death (CVD), kidney endpoints, and all-cause mortality in patients with type 2 diabetes.

Methods. We measured ETP in plasma (P-ETP) and urine (U-ETP) samples collected at baseline and follow-up (year 3) from the randomized controlled trial, CANagliflozin cardioVascular Assessment Study (CANVAS), by use of the PRO-C 6 ELISA measuring COL VI formation and ETP. At baseline, plasma and urine samples were available for 3531 and 3423 patients, respectively. At year 3, plasma and urine samples were available for 2178 (61.7%) and 2070 (60.5%) patients, respectively Patients were followed for a median of 6.1 years, and endpoints included: incident HF, CVD, three kidney composite endpoints, and all-cause mortality. Backward selection was used to identify variables to be included in the analyses. Robustness of the association with outcome was assessed by bootstrap analyses.

Results. In univariable analysis, P-ETP predicted all investigated outcomes (all p<0.0001), remained independently associated with all outcomes after adjustment for conventional risk factors (all p<0.004), and increased C-statistics of the models for the outcomes HF, CVD, HFCVD, all-cause mortality, and kidney composite 2 (ΔC ≥0.002). In bootstrap analysis, P-ETP was retained with a frequency ranging from 41.0 to 98.4% for all outcomes. Levels of U-ETP were associated with outcomes in univariable analysis, but associations with most outcomes were lost after adjustment for conventional risk factors. The increase in P-ETP over time was greater with increasing albuminuria stage (p<0.0001) and was independently associated with the kidney endpoints (p<0.03). In the placebo arm, the increase in P-ETP was prognostic for all-cause mortality [HR (95% CI); 1.14 (1.05–1.23), p=0.003]. Whereas levels of P-ETP were not impacted by treatment, levels of U-ETP significantly increased with canagliflozin treatment.

Conclusion. P-ETP generated during COL VI formation predicts cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes. As ETP identifies patients at increased risk of experiencing relevant outcomes, it may be used for patient enrichment in future clinical trials.

Keywords:biomarker; collagen; diabetes; endotrophin; extracellular matrix; fibrosis; heart failure; mortality; prognostic

References

1. Zoppini G., Targher G., Chonchol M., Ortalda V., Negri C., Stoico V., et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012; 7 (3): 401–8.

2. Mudaliar S., Polidori D., Zambrowicz B., Henry R.R. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport from bench to bedside. Diabetes Care. 2015; 38 (12): 2344–53. DOI: https://doi.org/10.2337/dc15-0642/-/DC1

3. Neal B., Perkovic V., Mahaffey K.W., de Zeeuw D., Fulcher G., Erondu N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377 (7): 644–57. DOI: https://doi.org/10.1056/nejmoa1611925

4. Ferrannini E., Mark M., Mayoux E. CV protection in the EMPA-REG outcome trial: A thrifty substrate hypothesis. Diabetes Care. 2016; 39 (7): 1108–14. DOI: https://doi.org/10.2337/dc16-0330

5. Mudaliar S., Alloju S., Henry R.R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care. 2016; 39 (7): 1115–22. DOI: https://doi.org/10.2337/dc16-0542

6. Heerspink H.J.L., Perkins B.A., Fitchett D.H., Husain M., Cherney D.Z.I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752–72.

7. Ceriello A., Genovese S., Mannucci E., Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016; 15 (1): 123.

8. Kalra S. Sodium-glucose cotransporter 2 (sglt2) inhibitors and cardiovascular disease: a systematic review. Cardiol Ther. 2016; 5 (2): 161–8.

9. Sattar N., McLaren J., Kristensen S.L., Preiss D., McMurray J.J. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016; 59: 1333–9.

10. Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968; 292 (7564): 363–6.

11. Karsdal M.A., Manon-Jensen T., Genovese F., Kristensen J.H., Nielsen M.J., Sand J.M.B., et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015; 308 (10): G807–30.

12. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7 (12): 684–96. DOI: https://doi.org/10.1038/nrneph.2011.149

13. Genovese F., Manresa A.A., Leeming D.J., Karsdal M.A., Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014; 7 (1): 4.

14. Gelse K., Pöschl E., Aigner T. Collagens–structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003; 55 (12): 1531–46.

15. Hewitson T.D., Holt S.G., Smith E.R. Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype – role of risk factors and epigenetics. Front Pharmacol. 2017; 8: 520. DOI: https://doi.org/10.3389/fphar.2017.00520/full

16. Park J., Scherer P.E. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest. 2012; 122 (11): 4243–56.

17. Sun K., Park J., Gupta O.T., Holland W.L., Auerbach P., Zhang N., et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun. 2014; 5 (3485): 1–12.

18. Mayer U., Poschl E., Nischt R., Specks U., Pan T., Chu M., et al. Recombinant expression and properties of the kunitz-type protease-inhibitor module from human type VI collagen a3 (VI) chain. Eur J Biochem. 1994; 225: 573–80.

19. Aigner T., Hambach L., Söder S., Schlötzer-Schrehardt U., Pöschl E. The C5 domain of col6a3 is cleaved off from the col6 fibrils immediately after secretion. Biochem Biophys Res Commun. 2002; 290 (2): 743–8.

20. Pilemann-Lyberg S., Rasmussen D.G.K., Hansen T.W., Tofte N., Winther S.A., Holm Nielsen S., et al. Markers of collagen formation and degradation reflect renal function and predict adverse outcomes in patients with type 1 diabetes. Diabetes Care. 2019; 42 (9): 1760–8.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)